← Back to Screener
Pelthos Therapeutics Inc. (PTHS)
Price$25.55
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-13.68%
Price vs S&P 500 (4W)0.23%
VGM Score70.00
Market Capitalization$88.80M
All Metrics
Book Value / Share (Quarterly)$18.85
Cash Flow / Share (Quarterly)$-5.50
Price vs S&P 500 (YTD)-24.83%
EPS (TTM)$-20.59
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-20.59
EPS (Annual)$-23.04
Gross Margin (Annual)76.25%
Cash / Share (Quarterly)$4.60
ROA (Last FY)-7657.22%
EBITD / Share (TTM)$-16.24
Cash Flow / Share (Annual)$-9.49
P/B Ratio1.52x
P/B Ratio (Quarterly)1.47x
Net Income / Employee (Annual)$-470,900
Net Interest Coverage (TTM)-1.82x
ROA (TTM)-72.82%
EPS Incl Extra (Annual)$-23.04
Current Ratio (Annual)0.34x
Quick Ratio (Quarterly)0.97x
3-Month Avg Trading Volume0.01M
52-Week Price Return145.67%
Revenue / Employee (TTM)$301,100
Tangible BV / Share (Quarterly)$8.33
P/S Ratio (Annual)5.29x
Asset Turnover (Annual)2.78x
52-Week High$54.29
EPS Excl Extra (Annual)$-23.04
26-Week Price Return-5.75%
Quick Ratio (Annual)0.32x
13-Week Price Return11.04%
Current Ratio (Quarterly)2.01x
Enterprise Value$74.60M
Revenue / Employee (Annual)$182,600
Pretax Margin (Annual)-301.91%
Cash / Share (Annual)$0.84
3-Month Return Std Dev66.40%
Net Income / Employee (TTM)$-560,700
Net Interest Coverage (Annual)-1.82x
EPS Basic Excl Extra (Annual)$-23.04
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-20.59
Revenue / Share (Annual)$8.93
Price vs S&P 500 (52W)121.31%
Year-to-Date Return-17.58%
5-Day Price Return-2.48%
EPS Normalized (Annual)$-23.04
Net Profit Margin (Annual)-257.93%
Month-to-Date Return-3.48%
EBITD / Share (Annual)$-16.57
Operating Margin (Annual)-194.79%
EPS Basic Excl Extra (TTM)$-20.59
P/TBV (Quarterly)3.34x
Price vs S&P 500 (13W)2.78%
Beta2.42x
Revenue / Share (TTM)$8.36
52-Week Low$10.00
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-3.09est. -3.34
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.18
4.17
4.17
4.15
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PTHSPelthos Therapeutics Inc. | — | — | B | $25.55 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Pelthos Therapeutics is a clinical-stage biotechnology company developing non-opioid pain therapeutics by targeting the NaV1.7 sodium ion channel. The company's pipeline focuses on treating chronic visceral pain, acute and chronic eye pain, and post-surgical nerve pain. Lead candidates include CC8464 and CT2000, with CT2000 specifically targeting acute and chronic dry eye disease.